These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 16370079)

  • 1. Newer antipsychotics similar to older agents.
    J Fam Pract; 2005 Dec; 54(12):1026. PubMed ID: 16370079
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oxyprothepin decanoate in maintenance therapy of schizophrenia--a double-blind, standardized controlled study].
    Filip V; Faltus F; Hanáková S; Janecková E; Raboch J; Dobiásová A; Karen P; Posmurová M
    Cesk Psychiatr; 1985 Feb; 81(1):6-14. PubMed ID: 2858269
    [No Abstract]   [Full Text] [Related]  

  • 6. Lessons from each drug trial.
    Marder SR
    Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457
    [No Abstract]   [Full Text] [Related]  

  • 7. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The position of blonanserin as a treatment for schizophrenia.
    Kishi T; Matsuda Y; Iwata N
    Asia Pac Psychiatry; 2014 Dec; 6(4):462. PubMed ID: 25425069
    [No Abstract]   [Full Text] [Related]  

  • 9. [Reaction on 'typical and atypical antipsychotics: is there a difference in their influence on neurocognition?'].
    van Oeffelt T
    Tijdschr Psychiatr; 2011; 53(4):255-6; author reply 256-7. PubMed ID: 21506082
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 12. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and limitations of newer antipsychotics: evidence from large comparative trials.
    Jarskog LF
    Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):113-4. PubMed ID: 23006235
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Priority for atypical antipsychotic drugs? Current studies clarify the issues].
    Dose M
    Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Canive JM; Miller DD; Reimherr F; McGee M; Khan A; Van Dorn R; Rosenheck RA; Lieberman JA
    J Nerv Ment Dis; 2006 Mar; 194(3):164-72. PubMed ID: 16534433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia.
    Citrome L
    Int J Clin Pract; 2008 May; 62(5):837-40. PubMed ID: 18412940
    [No Abstract]   [Full Text] [Related]  

  • 20. Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia?
    Skelly T; Pinheiro AP; Lange LA; Sullivan PF
    Mol Psychiatry; 2007 Apr; 12(4):321-2. PubMed ID: 17389899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.